Goal
Deactivate prions on medical instruments to prevent transmission of prion diseases such as Creutzfeldt-Jacob disease.
Problem
Prion contamination of surgical and medical instruments; prions are highly resistant to heat and conventional chemical sterilisation.
Concept Summary
An enzymatic cleaning solution that combines proteolytic enzymes with agents that promote conformational unfolding of the prion protein, breaking it into non-infectious fragments while remaining compatible with standard instrument cleaning equipment.
Detailed Description
Novapharm Research, in collaboration with the University of Melbourne, developed a formulation based on naturally occurring enzymes that specifically cleave the PrP^Sc prion protein. The composition also contains agents that favour unfolding of the prion's structure without denaturing the enzymes. The solution can be used as a pre-cleaner in existing cleaning protocols for flexible endoscopes, neurosurgical, dental and ophthalmological instruments. It has received approval from the Australian Therapeutic Goods Administration and CE certification for EU distribution, and is marketed under the trade names Asepti RAPIDZYME Pr and Asepti AUTOZYME Pr.
Principles
- Proteolytic enzymatic cleavage
- Conformational unfolding of protein
- Selective targeting of prion protein
- Compatibility with existing cleaning equipment
Scientific Domains
Materials
- Proteolytic enzymes (natural origin)
- Conformational unfolding agents (chemical additives)
Mechanisms of Action
- Enzymatic cleavage of PrP^Sc into low-molecular-weight fragments
- Chemical agents induce conformational unfolding of prion protein
- Preservation of enzyme activity during cleaning
Applications
- Hospital instrument reprocessing
- Veterinary surgical instrument cleaning
- Dental instrument sterilisation
- General medical device decontamination
Claimed Performance
Cost-effective, highly effective pre-cleaner compatible with any surgical or medical instrument; does not disrupt current surgical procedures.
Experimental Evidence
Regulatory approval (Australian Therapeutic Goods Administration) and CE certification indicate compliance with safety and efficacy standards, but no quantitative performance data are provided in the article.
Limitations
- No quantitative efficacy data presented
- Potential variability in effectiveness against different prion strains
- Reliance on proper handling and protocol adherence
